

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

HB 9080

October 27, 2021

SUMMARY OF BILL: Prohibits health-related licensing boards or disciplinary subcommittees from taking certain actions against a licensed physician, who recommends a treatment for COVID-19 that includes the use of a United States Food and Drug Administration (FDA)-approved drug, biological product, or device other than for the use or uses approved by the FDA to treat COVID-19, so long as the physician believes that the medical treatment is in the best interest of the patient.

Requires the Governor to remove from office a member of the board who violates this section on or after the effective date of this act and to appoint a new member to serve out the remaining term of the member being replaced.

Prohibits a pharmacy from blocking or attempting to block a patient's access to the recommended treatment using a drug, biological product, or device solely on the basis that the FDA has not approved the drug, biological product, or device to treat COVID-19.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumption:

- The proposed legislation will not significantly impact the operations of health-related boards, or the programs or policies of state or local governments; therefore, any fiscal impact is estimated to be not significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in black ink that reads "Krista Lee Carsner".

Krista Lee Carsner, Executive Director

/lm